HK1206996A1 - Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria masp-1masp-2 / masp-3 - Google Patents

Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria masp-1masp-2 / masp-3

Info

Publication number
HK1206996A1
HK1206996A1 HK15107717.0A HK15107717A HK1206996A1 HK 1206996 A1 HK1206996 A1 HK 1206996A1 HK 15107717 A HK15107717 A HK 15107717A HK 1206996 A1 HK1206996 A1 HK 1206996A1
Authority
HK
Hong Kong
Prior art keywords
masp
1masp
inhibting
compositions
treatment
Prior art date
Application number
HK15107717.0A
Other languages
English (en)
Chinese (zh)
Inventor
Hans-Wilhelm Schwaeble
Gregory A Demopulos
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of HK1206996A1 publication Critical patent/HK1206996A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HK15107717.0A 2012-04-06 2015-08-10 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria masp-1masp-2 / masp-3 HK1206996A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261621461P 2012-04-06 2012-04-06
PCT/US2013/035488 WO2013180834A2 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number Publication Date
HK1206996A1 true HK1206996A1 (en) 2016-01-22

Family

ID=49325295

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107717.0A HK1206996A1 (en) 2012-04-06 2015-08-10 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria masp-1masp-2 / masp-3

Country Status (29)

Country Link
US (3) US20130273053A1 (xx)
EP (2) EP3366307B1 (xx)
JP (3) JP6366571B2 (xx)
KR (2) KR102142508B1 (xx)
CN (1) CN104661676A (xx)
AU (3) AU2013267909B2 (xx)
BR (1) BR112014024793A2 (xx)
CA (2) CA3087933A1 (xx)
CL (1) CL2014002694A1 (xx)
CY (1) CY1120736T1 (xx)
DK (2) DK2833907T3 (xx)
ES (2) ES2894944T3 (xx)
HK (1) HK1206996A1 (xx)
HR (1) HRP20180671T1 (xx)
HU (1) HUE036930T2 (xx)
IL (2) IL234991B (xx)
IN (1) IN2014KN02324A (xx)
LT (1) LT2833907T (xx)
MX (2) MX357540B (xx)
NO (1) NO2881536T3 (xx)
NZ (2) NZ629675A (xx)
PL (2) PL3366307T3 (xx)
PT (1) PT2833907T (xx)
RS (1) RS57266B1 (xx)
RU (2) RU2018114903A (xx)
SI (1) SI2833907T1 (xx)
TR (1) TR201806939T4 (xx)
WO (1) WO2013180834A2 (xx)
ZA (1) ZA201408100B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
RU2709351C2 (ru) * 2012-06-18 2019-12-17 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
WO2014144542A2 (en) 2013-03-15 2014-09-18 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
AU2017364817B2 (en) 2016-11-28 2023-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
WO2018186322A1 (en) * 2017-04-03 2018-10-11 Chugai Seiyaku Kabushiki Kaisha Anti-masp-1 antibodies and methods of use
KR20210016545A (ko) * 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
CA3148119A1 (en) * 2019-07-31 2021-02-04 Biocryst Pharmaceuticals, Inc. Dosing regimens for oral complement factor d inhibitors
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CN114295594B (zh) * 2021-12-06 2023-09-19 贵州理工学院 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
AU785149B2 (en) * 1999-12-02 2006-10-05 Jens Christian Jensenius MASP-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) * 2001-07-23 2006-05-09 Intel Corporation Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
AU2004216176B2 (en) * 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
EP1713929A2 (en) * 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ATE419671T1 (de) * 2006-07-31 2009-01-15 Fiat Ricerche Durch eine fluidströmung betätigbarer elektrischer generator
JP5537420B2 (ja) 2007-05-31 2014-07-02 ユニヴァーシティ オブ ワシントン 標的遺伝子の誘導性変異誘発
KR20110047255A (ko) * 2008-09-26 2011-05-06 로슈 글리카트 아게 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
KR20110134415A (ko) * 2009-03-05 2011-12-14 스미스 앤드 네퓨, 인크. 대퇴경부 안내 와이어를 배치하기 위한 시스템, 방법 및 장치
EP2454281B1 (en) * 2009-07-17 2018-11-14 Omeros Corporation Masp isoforms as inhibitors of complement activation
KR20120130748A (ko) * 2009-11-05 2012-12-03 알렉시온 캠브리지 코포레이션 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료
MX355648B (es) 2011-04-08 2018-04-26 Univ Leicester El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.

Also Published As

Publication number Publication date
NZ781091A (en) 2022-04-29
CN104661676A (zh) 2015-05-27
NO2881536T3 (xx) 2018-06-30
KR102318623B1 (ko) 2021-11-02
RS57266B1 (sr) 2018-08-31
MX2018008658A (es) 2021-10-19
CL2014002694A1 (es) 2015-08-28
US20130273053A1 (en) 2013-10-17
IL234991B (en) 2020-06-30
NZ727063A (en) 2021-10-29
PL3366307T3 (pl) 2022-03-07
SI2833907T1 (en) 2018-07-31
EP2833907A2 (en) 2015-02-11
PL2833907T3 (pl) 2018-08-31
HUE036930T2 (hu) 2018-08-28
WO2013180834A3 (en) 2014-04-03
EP2833907A4 (en) 2016-03-16
AU2013267909A1 (en) 2014-11-27
BR112014024793A2 (pt) 2019-08-27
WO2013180834A2 (en) 2013-12-05
RU2014144621A (ru) 2016-05-27
IN2014KN02324A (xx) 2015-05-01
JP6815355B2 (ja) 2021-01-20
JP2015514117A (ja) 2015-05-18
RU2655299C2 (ru) 2018-05-24
JP2021001199A (ja) 2021-01-07
KR20200097808A (ko) 2020-08-19
RU2018114903A3 (xx) 2021-08-12
DK3366307T3 (da) 2021-11-01
DK2833907T3 (en) 2018-05-28
CA2869326A1 (en) 2013-12-05
NZ629675A (en) 2017-02-24
US20220242972A1 (en) 2022-08-04
IL234991A0 (en) 2014-12-31
AU2018200721A1 (en) 2018-02-22
JP6366571B2 (ja) 2018-08-01
KR102142508B1 (ko) 2020-08-10
EP3366307B1 (en) 2021-07-28
CA3087933A1 (en) 2013-12-05
EP3366307A1 (en) 2018-08-29
KR20150003785A (ko) 2015-01-09
IL274721B (en) 2022-04-01
MX357540B (es) 2018-07-13
CA2869326C (en) 2021-09-21
AU2013267909B2 (en) 2018-03-01
LT2833907T (lt) 2018-06-11
ES2894944T3 (es) 2022-02-16
CY1120736T1 (el) 2019-12-11
MX2014012045A (es) 2015-05-15
TR201806939T4 (tr) 2018-06-21
US20190382505A1 (en) 2019-12-19
HRP20180671T1 (hr) 2018-07-13
IL274721A (en) 2020-07-30
PT2833907T (pt) 2018-05-29
AU2020204163A1 (en) 2020-07-09
ZA201408100B (en) 2022-05-25
ES2670668T3 (es) 2018-05-31
JP2018162307A (ja) 2018-10-18
AU2018200721B2 (en) 2020-03-26
EP2833907B1 (en) 2018-02-28
RU2018114903A (ru) 2019-03-04

Similar Documents

Publication Publication Date Title
HRP20180671T1 (hr) Pripravci za i postupci inhibiranja masp-1 i/ili masp-3 u liječenju paroksizmalne noćne hemoglobinurije
IL266582A (en) Compositions and methods for the treatment of hemoglobinopathies
HK1210957A1 (en) Effluz inhibitor compositions and methods of treatment using the same
HK1209788A1 (en) Methods and compositions for the treatment of lysosomal storage diseases
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
EP2736528A4 (en) COMPOSITIONS AND METHODS OF TREATING HIV
IL238177A0 (en) Methods and preparations for the treatment of cancer
ZA201408056B (en) Compositions and methods for the treatment of mucositis
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA201408055B (en) Compositions and methods for the treatment of local pain
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
EP2814491A4 (en) FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES
HK1216721A1 (zh) 治療肝臟疾病或病狀的用途和方法
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
ZA201503844B (en) Compositions and methods for treating dental caries
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
HK1206598A1 (en) Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka